Abstract
Levels of the tumour markers neurone specific enolase (NSE), lactate dehydrogenase (LDH), chromogranin A (ChrA) and carcinoembryonic antigen (CEA) were measured in serum taken at presentation and during treatment, remission and relapse from 154 patients who received chemotherapy for small cell lung cancer at a single centre over a 6 year period. At presentation NSE was the most frequently elevated marker, being raised in 81% of patients and significantly higher in extensive as opposed to limited disease, as were LDH and ChrA. The response rate to therapy was best correlated with presentation level of ChrA, being 79% for those whose levels were within twice the upper limit of normal and 51% above (P < 0.01). Multivariate regression analysis showed NSE, performance status and albumin at presentation to be the best independent predictors of survival. Patients with NSE below twice the upper limit of normal, Karnofsky performance status of 80 or above and albumin 35 g l-1 or above had a median survival of 15 months with 25% alive at 2 years, whilst those with NSE above twice normal, Karnofsky below 80 and albumin less that 35 g l-1 had all died by 8 months. Changes in marker levels during therapy were of low predictive value for outcome although the finding of rising NSE during chemotherapy after an initial fall correlated with significantly reduced duration of remission. There was a strong inverse correlation between the NSE level at the time of response and duration of remission (P < 0.0001). Prediction of relapse was most reliable with ChrA, 52% of patients having rising levels before clinical evidence of disease recurrence.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnson, P., Joel, S., Love, S. et al. Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer. Br J Cancer 67, 760–766 (1993). https://doi.org/10.1038/bjc.1993.138
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.138
This article is cited by
-
Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis
World Journal of Surgical Oncology (2020)
-
Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder
World Journal of Urology (2017)
-
Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio)
Lung (2016)
-
Serum neuron-specific enolase levels were associated with the prognosis of small cell lung cancer: a meta-analysis
Tumor Biology (2013)
-
Chromogranin A, a significant prognostic factor in small cell lung cancer
British Journal of Cancer (1999)